A Rare Case of Orbital Castleman Disease with Overlapping IgG4-Related Disease.
IgG4-related disease
histopathology
multicentric Castleman disease
orbital tumor
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
28 Jul 2023
28 Jul 2023
Historique:
received:
05
07
2023
revised:
23
07
2023
accepted:
27
07
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Multicentric Castleman disease (MCD) is a systemic lymphoproliferative disorder that can lead to mass lesions in various body parts, including the lungs, kidneys, and extranodal sites. Meanwhile, orbital Castleman disease is extremely rare. Immunoglobulin G4-related disease (IgG4-RD) is a recently recognized fibroinflammatory disorder and is characterized by the formation of tumor-like lesions with lymphoplasmacytic infiltrates, which are enriched in IgG4-positive plasma cells and may present with a characteristic storiform pattern of fibrosis to variable degrees. In this study, we report a case of a 67-year-old Taiwanese man with a 7-year history of bilateral eyelid swelling and proptosis. Orbital magnetic resonance imaging revealed soft tissue lesions in the bilateral intraconal region, demonstrating strong enhancement in the lacrimal glands, and extension into the bilateral infraorbital foramen, suggesting an orbital lymphoproliferative disease. The histopathological results of the intraorbital tumor excision were suggestive of a plasma-cell-predominant mixed-cell variant of MCD. However, the patient also showed definitive signs of IgG4-RD, including lacrimal gland enlargement and histopathological results of plasmacytosis, fibrosis, and germinal centers, with an increased ratio of IgG4 cells and elevated serum IgG4 levels. This case suggests a potential interacting pathway between these two disease entities that needs further studies.
Identifiants
pubmed: 37629670
pii: medicina59081381
doi: 10.3390/medicina59081381
pmc: PMC10456907
pii:
doi:
Substances chimiques
Immunoglobulin G
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Références
Oncotarget. 2018 Jan 9;9(6):6691-6706
pubmed: 29467920
Arthritis Rheumatol. 2015 Jul;67(7):1688-99
pubmed: 25809420
Clin Exp Ophthalmol. 2004 Feb;32(1):108-10
pubmed: 14746606
Cytokine Growth Factor Rev. 2016 Aug;30:29-37
pubmed: 27072069
Rheumatology (Oxford). 2023 Apr 3;62(4):1426-1435
pubmed: 35997567
Oncoimmunology. 2018 Jul 30;7(10):e1494110
pubmed: 30288360
Ophthalmology. 1989 Nov;96(11):1646-9
pubmed: 2616150
Cytokine. 2015 Sep;75(1):14-24
pubmed: 26044597
N Engl J Med. 2012 Feb 9;366(6):539-51
pubmed: 22316447
Mol Immunol. 2002 Dec;39(9):531-6
pubmed: 12431386
Case Rep Ophthalmol Med. 2020 Jan 3;2020:1012759
pubmed: 31984145
J Postgrad Med. 2018 Apr-Jun;64(2):119-122
pubmed: 29067928
J Clin Rheumatol. 2022 Mar 1;28(2):e596-e604
pubmed: 34538846
J Ophthalmol. 2020 Nov 23;2020:3718305
pubmed: 33489328
Pathologica. 2021 Oct;113(5):339-353
pubmed: 34837092
Surv Ophthalmol. 2010 May-Jun;55(3):247-55
pubmed: 20070998
Rheumatology (Oxford). 2022 Feb 2;61(2):490-501
pubmed: 34363463
Intern Med. 2017;56(9):1095-1099
pubmed: 28458319
Blood. 2020 Apr 16;135(16):1353-1364
pubmed: 32106302
Jpn J Ophthalmol. 2015 Jan;59(1):8-13
pubmed: 25373451